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Background: Premature cardiovascular (CV) death is the commonest cause of death in renal transplant recipients.
Abnormalities of left ventricular (LV) structure (collectively termed uremic cardiomyopathy) and left atrial (LA)
dilation, a marker of fluid status and diastolic function, are risk factors for reduced survival in patients with end
stage renal disease (ESRD). In the present analysis, we studied the impact of pre-transplant LA and LV abnormalities
on survival after successful renal transplantation (RT).
Methods: One hundred nineteen renal transplant recipients (first transplant, deceased donors) underwent
cardiovascular MRI (CMR) as part of CV screening prior to inclusion on the waiting list. Data regarding transplant
function and patient survival after transplantation were collected.
Results: Median post-transplant follow-up was 4.3 years (interquartile range (IQR) 1.9, 6.2). During the post-transplant
period, 13 patients returned to dialysis after graft failure and 23 patients died with a functioning graft. Survival analyses,
censoring for patients returning to dialysis, showed that pre-transplant LV hypertrophy and elevated LA volume were
significantly associated with reduced survival after transplantation. Multivariate Cox regression analyses demonstrated
that longer waiting time, poorer transplant function, presence of LV hypertrophy and higher LA volume on screening
CMR and female sex were independent predictors of death in patients with a functioning transplant.
Conclusions: Presence of LVH and higher LA volume are significant, independent predictors of death in patients who
are wait-listed and proceed with renal transplantation.
Keywords: Outcome, Renal transplantation, Left atrial and ventricular functionBackground
Premature cardiovascular (CV) death is the commonest
cause of mortality in patients with end stage renal dis-
ease (ESRD) requiring renal replacement therapy [1].
Abnormalities of the left ventricular (LV) structure and
function, including left ventricular hypertrophy (LVH),
left ventricular systolic dysfunction (LVSD) and left ven-
tricular dilation, are common in ESRD patients and inde-
pendently confer a poorer prognosis [2,3]. These changes
have been collectively termed “uremic cardiomyopathy”.* Correspondence: rajan.patel@glasgow.ac.uk
1BHF Glasgow Cardiovascular Research, University of Glasgow, 126 University
Place, Glasgow G12 8TA, UK
2Department of Renal Medicine, Western Infirmary, Dumbarton Road,
Glasgow G11 6NT, UK
Full list of author information is available at the end of the article
© 2014 Patel et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Furthermore, left atrial (LA) dilation (corrected for body
surface area (BSA) or height) is an independent predictor
of mortality in the general population and in hypertensive
and ESRD patients [4,5]. Impaired left ventricular diastolic
relaxation and filling, mitral valve disease and fluid over-
load contribute to increased left atrial volume (LAV) [6],
which can reliably and reproducibly be measured on
echocardiography and CMR using the biplane area-length
method [7,8]. We have previously demonstrated LA dila-
tion, in the absence of significant mitral valve disease, to
be an independent predictor of death in ESRD patients
with LVH [5].
Renal transplantation (RT) is the optimal form of renal
replacement therapy (RRT) and is associated with re-
duced CV morbidity and mortality compared to patientsd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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CV death is more common in RT recipients (RTRs)
compared to the general population even in the presence
of good transplant function [9-11]. Attempts to improve
CV survival in RTRs have focused on modifying conven-
tional CV risk factors, such as dyslipidemia, diabetes
mellitus and hypertension after transplantation with
varying degrees of success [12]. Pre-transplant factors
have also been associated with adverse graft and recipi-
ent outcome including longer waiting list time, recipient
age and greater co-morbidity [13,14]. Presence of uremic
cardiomyopathy may be associated with adverse progno-
sis in RTR, and therapies aimed at reducing LV abnor-
malities prior to transplantation may help recipient and
graft survival [3]. In addition, very few studies have in-
vestigated the effect of LA dilation on RTR survival [15].
Initial echocardiography studies demonstrated im-
proved extracellular fluid control and regression of LVH
which may account for improved CV outcome in ESRD
patients after renal transplantation [16]. However, echo-
cardiography overestimates LV mass in ESRD patients
due to intravascular volume fluctuations, distortion of
LV geometry and the reliance of standard estimates of
LV mass on chamber diameters. Cardiovascular MRI
(CMR) provides more detailed, volume independent,
measurement of cardiac structure and is considered the
most accurate technique for assessing ventricular dimen-
sions in patients with ESRD. We have previously demon-
strated no regression of LV abnormalities in RTRs up to
2.4 years post-transplantation using CMR [17]; the infer-
ence being that reduction in LV mass after transplant-
ation reported by echocardiography is an artefact of
normalisation of intravascular volume.
The aim of the current study was to assess the effect
of pre-transplant LV and LA abnormalities measured by
CMR on post-transplant outcomes.
Methods
Patients
Since 2002 [18,19], we have used CMR as part of the
standard assessment of patients for renal transplantation.
Patients were referred by transplant nephrologists or
surgeons based on previously described criteria [19].
The renal transplant unit at the Western Infirmary,
Glasgow, provides transplant services to a population of
2.8 million people in the west of Scotland. The trans-
plant waiting list has 300–400 patients at any time point;
approximately 100–120 new patients are wait-listed and
approximately 95 deceased donor adult transplants are
performed annually. CMR assessment was performed on
119 patients with CKD stage 5 receiving (hemo- or peri-
toneal) dialysis who subsequently underwent successful
renal transplantation. Only patients receiving their first
transplant and grafts from deceased (donation beforecardiac death) donors were included in the study. This
study was approved by the west of Scotland Research
Ethics Committee (as part of previously published studies
[5,19]), and all patients gave written, informed consent.
Patients who received a transplant before requiring
dialysis were excluded. To ensure that only non-valvular
causes of LA dilation were assessed, patients with mild
to severe mitral valve disease on echocardiography,
based on American Society of Echocardiography guide-
lines [20], were excluded from the study. No patients
suffered a CV event between assessment and transplant-
ation. Date and cause of patient death were detected
from electronic patient records.CMR technique and analysis
Non-gadolinium contrast CMR was performed using a 1.5
Tesla MRI scanner (Sonata, Siemens, Erlangan, Germany)
with LV mass and function assessed as previously de-
scribed [21]. Scans were consistently performed 24 h after
the end of the last dialysis session in hemodialysis patients.
A fast imaging with steady-state precession (TrueFISP)
sequence was used to acquire cine images in long axis
planes (vertical long axis, horizontal long axis, left ven-
tricular outflow tract) followed by sequential short axis LV
cine loops (8-mm slice thickness, 2-mm gap between
slices) from the atrioventicular ring to the apex. Imaging
parameters, which were standardised for all subjects, in-
cluded repetition time (TR)/echo time (TE)/flip angle/
voxel size/field of view (FoV) = 3.14 ms/1.6 ms/60°/2.2 1.3
8.0 mm/340 mm. LV mass was analysed by two observers,
blinded to patient clinical characteristics, from short
axis cine loops using manual tracing of epicardial and
endocardial end-systolic and end-diastolic contours.
End-systolic and end-diastolic volumes and LV mass
were calculated using analysis software (Argus, Siemens,
Erlangen, Germany). LVH was defined as left ventricular
mass index (LV mass/body surface area; LVMI) >84.1
g/m2 (male) or >66.8 g/m2 (female), and LVSD was de-
fined as LV ejection fraction (LVEF) <55%. LV dilation was
defined as end diastolic volume/body surface area (EDV/
BSA) >111.7 ml/m2 (male) or 99.3 ml/m2 (female) or end
systolic volume/body surface area (ESV/BSA) >92.8 ml/m2
(male) or 70.3 ml/m2 (female) [22].
The biplane area-length method for ellipsoid bodies
was used [7] to measure LAV. Horizontal and vertical
long axis cine images were used to obtain images of the
left atrium at maximal filling. The atrial lengths and
areas were measured from both views, and LAV was cal-
culated. LAV was corrected for body surface area (LAV/
BSA). Patients were categorised into two LAV groups
according to mean LAV (i.e. low = less than mean LAV
and high = greater than or equal to mean LAV). Left
atrial appendages were included in these measurements.
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Echocardiography was performed by an experienced
echocardiographer using an Acuson Sequoia C512 ma-
chine (Siemens Medical, Mountainview, CA, USA). Dia-
stolic function was assessed using pulsed wave Doppler
[23,24] from apical four chamber views to measure the
ratio of early (E) to late (A) mitral inflow peak flow vel-
ocity (E/A ratio).
Clinical and blood result data collection
Demographic information and clinical history were
recorded at the time of CMR. Electronic patient record re-
view was performed to retrieve post-transplant informa-
tion including medication and outpatient clinic systolic
and diastolic blood pressure (SBP and DBP, respectively)
60 days prior to the date of censor or patient death. Bio-
chemical and hematological blood results were collected
at the time of CMR. In addition, data regarding transplant
function (as assessed by serum creatinine) were collected
for the 60 days up to the date of death or censor (22nd
March 2011) accordingly. Data regarding patients initially
listed but subsequently suspended were not available for
analyses. Delayed graft function was defined as require-
ment for hemodialysis within 7 days of transplantation.
Indication biopsy findings were used to determine pres-
ence of biopsy-proven acute rejection (BPAR) according
to standard Banff classification.
Statistical analyses
Data are described as mean and standard deviation (for
normally distributed data) or median (interquartile
range, IQR) for non-normal data. Survival analyses were
performed from the time of transplantation and cen-
sored for graft failure and return to dialysis. Compari-
sons of mean survival (±standard deviation) for different
cardiac parameters are shown as Kaplan-Meier graphs
(with statistical comparison using the log rank test).
These data were also analysed by Cox multivariate sur-
vival analysis to assess the influence of multiple clinical
and cardiac variables on outcome. Variables identified as
significantly influential on outcome by univariate ana-
lysis were entered into a backward stepwise regression
model. All analyses were performed using SPSS v19.0
(SPSS Inc, www.spss.com). Log minus log plots of sur-
vival were performed to check proportionality assump-
tions of the Cox model.
Results
Using data from 402 ESRD patients assessed for renal
transplantation between 2002 and 2010, 326 patients
were listed for transplantation and 119 underwent renal
transplantation. As stated before, these patients were re-
ferred for assessment for first donation before cardiac
death renal transplant, having been deemed “moderate”CV risk based on specific criteria [19] by the referring
transplant physician or surgeon.
Cardiac assessment parameters
Table 1 shows patient data gathered at the time of car-
diac assessment including mode of RRT, past medical
history and cardiac drug history. The mean age at as-
sessment was 50.5 (±10.2) years and the majority of
patients assessed were male (69.7%). Median time from
starting dialysis to cardiac assessment was 2.2 years (IQR
0.6, 5.2). There was high prevalence of patients with dia-
betes (61.3%) and past history of ischemic heart disease
(14.3%) who underwent cardiac assessment. As we have
demonstrated before, LVH was common (65.5%) on CMR
assessment of these patients. CMR data are also shown in
Table 1. Mean LAV/BSA was 32.1 (±7.7) ml/m2.
Peri- and post-transplant parameters
The median time from cardiac assessment to transplant-
ation was 2.6 years (IQR 1.1, 4.3 years) and time on
transplant waiting list was 2.4 (IQR 1.1, 4.2 years).
Thirteen (10.9%) patients developed graft failure and
returned to dialysis. The median transplant follow-up,
censored for return to dialysis, was 4.3 years (IQR 1.9, 6.2
years). Table 2 shows immunosuppressive therapy for pa-
tients at the time of censoring or death. Mean creatinine
from 60 days prior to death or censoring was 188 (±38)
μmol/l. Forty two (35.3%) RTRs developed delayed graft
function (DGF) and sixteen (13.4%) developed biopsy-
proven acute rejection during follow-up.
Outcome after transplantation
We initially examined the effect of patient characteristics
on outcome in RTRs (Table 1). Twenty three RTRs died
during the post-transplant follow-up period. Cause of
death was cardiac in 9 (39.1%), sepsis in 7 (30.4%), ma-
lignancy in 2 (8.7%) and unknown in 3 (13.0%) cases.
“Other”, non-defined, causes accounted for 2 (8.7%)
deaths. There were significant associations between pa-
tient death and older age, female sex, past history of
cerebrovascular disease and lower serum albumin at the
time of cardiac assessment. LAV/BSA was significantly
higher in patients who died during follow-up (p = 0.01).
In addition, longer duration on the deceased donor renal
transplant waiting list and poor transplant function
prior (60 days) to censor or death were significantly
associated with death after transplantation (Table 2).
There was no significant difference between the rate
of angiotensin-converting enzyme inhibitor (ACEI) or
angiotensin II receptor blocker (ARB) usage (pre- and
post-transplant) between survivors and the patients
who died during follow-up.
We investigated the effect of left ventricular and atrial
abnormalities detected by CMR on RTR outcome
Table 1 Demographic, clinical and drug data for patients at pre-transplant cardiac assessment
Variable Total
N = 119
Alive
N = 96
Dead
N = 23
p
Age at CMR (years) 50.5 (±10.2) 49.8 (±9.7) 53.7 (±11.5) 0.05*
Male (%) 83 (69.7) 71 (74.0) 12 (52.2) 0.04*
BSA (m2) 1.84 (±0.3) 1.86 (±0.3) 1.77 (±0.2) 0.12
BMI (kg/m2) 25.0 (±4.7) 24.9 (±0.7) 25.4 (±4.5) 0.12
Systolic BP (mmHg) 138 (±23) 137 (±23) 141 (±24.2) 0.38
Diastolic BP (mmHg) 82 (±12.7) 82 (±13) 81 (±13) 0.77
RRT time to CMR (years) 2.2 (0.6, 5.2) 1.7 (0.7, 3.9) 2.5 (0.6, 5.8) 0.57
RRT
HD 100 (84.0) 84 (87.5) 16 (69.5) 0.91
PD 19 (16.0) 11 (11.4) 8 (34.7)
Diabetes mellitus 73 (61.3) 61 (63.5) 12 (52.2) 0.32
Ischemic heart disease 17 (14.3) 13 (13.5) 4 (17.4) 0.64
Heart failure 6 (5.0) 5 (5.2) 1 (4.3) 0.86
Cerebrovascular disease 12 (10.1) 6 (6.3) 6 (26.1) 0.005*
Peripheral vascular disease 7 (5.9) 4 (4.2) 3 (13.0) 0.10
Dyslipidemia 34 (28.6) 26 (27.1) 8 (34.8) 0.46
Smoking
Never 52 (43.7) 44 (45.8) 8 (34.8) 0.14
Current/Ex smoker 67 (56.3) 52 (54.2) 15 (65.2)
Epo receptor agonist 92 (77.3) 74 (77.9) 18 (78.3) 0.97
β adrenoceptor blocker 40 (33.6) 35 (37.6) 5 (21.7) 0.15
Aspirin 32 (26.9) 26 (28.0) 6 (26.1) 0.86
Warfarin 5 (4.2) 2 (2.2) 3 (13.0) 0.08
ACEI/ARB pre-transplant 25 (21.0) 22 (23.4) 3 (13.0) 0.28
Diuretic 30 (25.2) 24 (25.8) 6 (26.1) 0.98
Calcium channel blocker 29 (24.4) 23 (24.7) 6 (26.1) 0.89
α adrenoceptor blocker 10 (8.4) 9 (9.7) 1 (4.3) 0.42
Statin 34 (28.6) 26 (28.0) 8 (34.8) 0.52
Hemoglobin (g/l) 117 (±17) 117 (±1.7) 117 (±1.8) 0.97
CRP 6.0 (4.0, 41.2) 6.0 (4.0, 12.0) 19 (4.0, 49.5) 0.19
Corrected calcium (mmol/l) 2.42 (±0.4) 2.41 (±0.4) 2.42 (±0.5) 0.97
Phosphate (mmol/l) 1.67 (±0.4) 1.71 (±0.4) 1.52 (±0.5) 0.30
Albumin (g/l) 41.5 (±4.3) 42.5 (±3.7) 37.5 (±4.7) 0.008*
Ejection fraction (%) 66.3 (±10.2) 66.3 (±9.5) 66.4 (±12.3) 0.99
LVSD on MRI (EF < 55%) 16 (13.4) 11 (11.5) 5 (21.7) 0.19
Myocardial mass/BSA (g/m2) 96.4 (±31.7) 95.2 (±31.7) 101.6 (±32.4) 0.38
LVH 78 (65.5) 58 (60.4) 20 (87.0) 0.16
ESV/BSA (ml/m2) 25.1 (±14.8) 72.4 (±25.7) 73.5 (±25.2) 0.85
EDV/BSA (ml/m2) 72.7 (±25.5) 24.9 (±13.8) 25.9 (±18.9) 0.77
LV dilation 14 (13.4) 11 (11.5) 3 (13.0) 0.83
LA volume/BSA (ml/m2) 32.1 (±7.7) 31.0 (±6.7) 36.4 (±9.1) 0.01*
Data are numbers with percentage in parentheses, mean ± standard deviation or median (interquartile range). Tests of significance are t-test (parametric),
Mann-Whitney (non-parametric) and Chi-square. Abbreviations: CMR cardiovascular MRI, RRT renal replacement therapy, HD hemodialysis, PD peritoneal dialysis,
Epo erythropoietin stimulating agent, ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker, BSA body surface area, BMI body mass
index. *p < 0.05.
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ence of LVH on CMR at cardiac assessment was signifi-
cantly associated with a reduction in mean survival time
(Figure 1a- no LVH 7.7 ± 2.0 years vs. LVH 6.6 ± 3.3
years; p = 0.023). The presence of LVSD or LV dilation
was not significantly associated with reduction in mean
survival time (Figure 1b- No LVSD 7.2 ± 2.9 years vs.
LVSD 6.0 ± 3.4 years; p = 0.19. No LV dilation 7.1 ± 3.1
years vs. LV dilation 6.1 ± 2.7 years; p = 0.80). Patients
were categorised into two groups according to mean
LAV/BSA (less than or greater than or equal to 32.1 ml/
m2). Higher LAV/BSA was significantly associated with
reduced survival time (Figure 1c- < 32.1 ml/m2 7.2 ± 1.2
years vs. ≥32.1 ml/m2 6.1 ± 2.6 years; p = 0.009).
Compared to patients with normal cardiac stucture or
LA dilation alone, there was a trend towards poorer sur-
vival in patients with LA dilation and LVH or LVSD, but
this did not reach statistical significance (data not
shown).
Survival analyses
Table 3 shows univariate and multivariate Cox survival
analyses for patient clinical and cardiac characteristics
at the time of cardiac assessment. Univariate analyses
showed that longer time on the deceased donor renal
transplant waiting list, poorer transplant function (60
days pre censor), presence of LVH, higher LAV/BSA, fe-
male sex, past history of cerebral and peripheral vascular
disease, older age at transplantation and development of
delayed graft function were significantly associated with
death. Multivariate analysis (Table 3) demonstrated that
longer time on the renal transplant waiting list, poorerTable 2 Peri- and post-transplantation data
Variable Total
N = 119
Age at transplantation (years) 53.1 (±10.5)
Assessment to transplant (years) 2.6 (1.1, 4.3)
Waiting list time (years) 2.4 (1.1, 4.2)
Mycophenolic acid 62 (52.1)
Azathioprine 45 (37.9)
Prednisolone 119
Tacrolimus 57 (47.9)
Cyclosporin 45 (37.9)
Sirolimus 3 (2.5)
ACEI/ARB therapy post-transplant 22 (17.6)
Mean creatinine at censor (μmol/l) 188 (±38.2)
Biopsy-proven acute rejection 16 (13.4)
Delayed graft function 42 (35.3)
Data are numbers with percentage in parentheses, mean ± standard deviation or m
Whitney (non-parametric) and Chi-square. ACEI/ARB angiotensin-converting enzymetransplant function, presence of LVH and higher LAV/
BSA, female sex and delayed graft function were independ-
ently associated with death after renal transplantation.
Discussion
Renal transplantation is associated with a significant re-
duction of CV disease in patients with ESRD compared
to patients who remain on the renal transplant waiting
list [10]. Nonetheless, RTRs have three- to fivefold in-
creased risk of premature CV morbidity compared to
the general population, and CV disease is the leading
cause of death and graft loss [25,26]. The pathogenesis
of CVD in RTRs differs from the general population in
that sudden, presumed arrhythmic, cardiac death and
the sequelae of coronary artery disease have similar
prevalence. The Assessment of LEscol in Renal Trans-
plantation (ALERT) study demonstrated that, in RTRs,
myocardial infarction was dependent upon lipids and
conventional risk factors for CAD, whereas the risk fac-
tors for sudden cardiac death included renal dysfunction,
blood pressure and LVH [12,27]. In an attempt to pro-
long post-transplant and graft survival, several studies
have identified potential risk factors for CV disease
amenable to modification. Most of these studies have fo-
cused on post-transplant factors, and few have deter-
mined whether modification of risk factors whilst on the
transplant waiting list can have significant effect on re-
cipient or graft outcome.
Against this background, we sought to determine fac-
tors associated with death after renal transplantation in
a cohort of patients who underwent comprehensive CV
assessment prior to their inclusion on the deceasedAlive
N = 96
Dead
N = 23
p
52.7 (±10.0) 55.0 (±12.2) 0.33
1.3 (0.8, 3.5) 2.6 (1.2, 4.3) 0.09
1.8 (0.7, 3.5) 2.5 (1.1, 4.3) 0.02*
53 (55.2) 9 (39.1) 0.14
31 (32.2) 14 (60.8) 0.07
96 (100) 23 (100)
46 (47.9) 11 (47.8) 0.92
34 (35.4) 11 (47.8) 0.64
3 (3.1) 0 (0)
20 (20.8) 2 (8.7) 0.18
173 (±116) 253 (±151) 0.02
15 (15.6) 1 (4.3) 0.15
29 (30.2) 13 (56.5) 0.02*
edian (interquartile range). Tests of significance are t-test (parametric), Mann-
inhibitor/angiotensin II receptor blocker. *p < 0.05.
ac
b
Figure 1 Kaplan Meier survival curve (censored for graft failure) according to the presence of (1a) left ventricular hypertrophy (LVH),
(1b) left ventricular systolic dysfunction and (1c) left atrial dilation.
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ing factors, only patients receiving their first transplant
from deceased donors (death before cardiac death) were
included in the analyses. In particular, we investigated the
effect of CMR-measured left atrial and ventricular abnor-
malities on post-transplant survival. These abnormalitieshave previously been shown to be independent predictors
of death in dialysis patients. Although these appear to im-
prove after transplantation when measured by echocardiog-
raphy [2,16], there are no significant reductions in LV mass,
function or chamber size assessed by CMR which
provides a volume-independent measurement of LV
Table 3 Results of univariate and multivariate Cox regression survival analyses of all RTRs; all-cause mortality (N = 23)
is the dependable variable
Variable Univariate analyses Multivariate analyses
HR 95% CI p HR 95% CI p
Time on waiting list (per year) 1.27 1.00-1.62 0.05* 1.62 1.07–1.78 0.02*
Creatinine (per 10 μmol/l) 1.03 1.01–1.06 0.01* 1.07 1.03–1.11 <0.001*
LVH 3.78 1.12–12.72 0.03* 6.23 1.18–22.31 0.004*
Male 0.43 0.19–0.98 0.04* 0.23 0.11–0.65 0.02*
LAV/BSA above 32.1 ml/m2 3.11 1.27–7.57 0.01* 6.60 1.70–18.58 0.02*
Delayed graft function 2.42 1.08–5.64 0.03 3.12 1.02–9.57 0.05*
Cerebrovascular disease 6.76 2.58–17.78 0.05* 3.12 0.91–23.7 0.07
Peripheral vascular disease 3.36 1.00–11.37 0.05* 7.38 0.51–52.3 0.21
Age at transplantation (per year) 1.04 1.00–1.08 0.05* 1.02 0.96–1.26 0.43
BMI (per kg/m2) 1.02 0.94–1.12 0.69
Biopsy-proven acute rejection 2.76 0.37–5.68 0.21
LVSD 2.38 0.88–6.47 0.08
Ischemic heart disease 1.33 0.45–3.91 0.61
LV dilation 1.16 0.34–3.90 0.82
Diabetes mellitus 0.59 0.25–1.31 0.19
Heart failure 0.86 0.12–6.40 0.88
Current/Ex smoker (ref never) 1.58 0.67–3.72 0.30
Systolic BP (per mmHg) 1.02 0.99–1.04 0.15
Diastolic BP (per mmHg) 0.98 0.94–1.02 0.26
Dyslipidemia 1.67 0.71–3.99 0.24
RRT time to CMR (years) 0.92 0.81–1.05 0.21
Previous RRT type
PD 1.00
HD 1.29 0.17–9.79 0.80
Hemoglobin (per g/dl) 0.65 0.97–1.13 0.13
Albumin (per g/l) 0.83 0.65–1.05 0.13
Phosphate (per mmol/l) 0.43 0.07–2.75 0.37
Calcium (per mmol/l) 5.45 0.11–12.54 0.40
ACEI/ARB therapy pre-transplant 0.52 0.16–1.76 0.29
ACEI/ARB therapy post-transplant 0.42 0.10–1.80 0.24
Hazard ratios (95% confidence intervals (CI)) are shown. Variables highlighted with (*) were added to the multivariate Cox model. Abbreviations: LV left ventricle,
LVH left ventricular hypertrophy, LVSD left ventricular systolic dysfunction, BMI body mass index, BP blood pressure, RRT renal replacement therapy, PD peritoneal
dialysis, HD hemodialysis. *p < 0.05
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lenges of echocardiography and the effect of intravas-
cular (and hence intraventricular) volume status when
assessing LV parameters of ESRD patients including
transplant recipients [28].
Left ventricular abnormalities
Our data demonstrate that the presence of LVH at car-
diac assessment was an independent predictor of death
after renal transplantation. In addition, the presence of
LVH was significantly associated with poorer survival(Figure 1a). Thus, LVH may be a potential therapeutic
target to improve survival after transplantation. Unfortu-
nately, interventions shown to regress LVH in patients
with normal renal function are less successful in ESRD
subjects. LVH after transplantation is associated with
pre- and post-transplant hypertension (which is com-
mon and severe in RTRs even when graft function is
good), side effects of immunosuppressive agents, extra-
cellular fluid overload and vascular stiffness [29]. These
features increase LV preload and afterload to varying de-
grees resulting in alteration in chamber stress (pressure
Patel et al. Transplantation Research 2014, 3:20 Page 8 of 10
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changes. In this study, left ventricular systolic dysfunc-
tion and dilation were not significantly associated with
death or reduced survival time (Table 3 and Figure 1b,
c), and this is most likely due to a small number of can-
didates with these abnormalities who subsequently re-
ceived a renal transplant. Moreover, in a previous study
of cardiac screening, we found that the presence of se-
vere cardiac abnomalities often resulted in patients not
being listed for transplantation [19].
Attempts to reduce LV mass and improve CV out-
come after transplantation have aimed to control blood
pressure. In a small randomised control trial investigat-
ing the effect of ACEI on long-term outcome of RTRs,
treatment was significantly associated with better CV
and general outcome with no significant adverse effects
to transplant function [30]. In our study, treatment with
ARB/ACEI before or after transplantation was not sig-
nificantly associated with RTR survival (Tables 1, 2 and
3). Furthermore, modification of immunosuppressive
regimen (including early withdrawal of glucocorticoid
therapy, minimisation of calcineurin antagonists) has
been successful with significant reduction in blood
pressure [31,32], although it is unclear whether this will
have an effect on CV survival. More recently, the use of
sirolimus, in place of CNIs, was associated with regres-
sion of LVH [33,34] in a small non-randomised trial in
RTRs. In addition, initial results from the BENEFIT
trial (belatacept versus high-dose cyclosporin), looking
at blood pressure, lipids and NODAT showed that pa-
tients on belatacept had an improved metabolic risk
profile at 12 months [35]. In general, transplant clini-
cians and transplant recipients may be reluctant to
change immunosuppressive regimen or implement spe-
cific antihypertensive therapy to achieve blood pressure
control, because of the perceived immunological and
vascular risk and possibility of jeopardising graft func-
tion. Newer strategies to control blood pressure in
RTRs may allow sustained blood pressure control, im-
prove LV parameters and reduce post transplant mor-
tality without the need for a significant change to
medications.
Left atrial dilation
We have previously shown that LA dilation measured
by CMR confers poorer prognosis in hemodialysis
patients with LVH and no significant mitral valve
disease. Elevated LA volumes are a consequence of
chronic elevated ventricular filling pressures, impaired
LV relaxation during diastole (diastolic dysfunction)
and volume overload in dialysis patients. However, in
RTRs, fluid overload is avoided and improved due to
good graft function and physiological response to
euvolemia.In this study, LA dilation before transplantation was
significantly associated with reduced post-transplant sur-
vival. Furthermore, elevated LAV was associated with
death independently from LVH. Taken together, these
data suggest LA changes (associated with chronic abnor-
malities of ventricular and atrial pressure) and its adverse
effect on prognosis may persist after transplantation des-
pite improvement in fluid status. Moreover, LA dilation is
identified as a potentially remediable risk factor, perhaps
by the use of strategies that improve LV compliance and
associated diastolic dysfunction.
In both living and deceased donor renal transplant-
ation, time spent on the transplant waiting list is
independently associated with adverse outcome after
transplantation [13]. Unfortunately, this is unlikely to
change as attempts to reduce waiting list times for de-
ceased donor transplantation have been unsuccessful
due to the discrepancy between kidney transplant
demand and organ supply. However, strategies to re-
duce waiting time by, for example, living donation and
pre-emptive transplantation are likely to have long-term
benefits. Poorer graft function, measured by mean serum
creatinine in the preceding 60 days prior to censor, was in-
dependently associated with post-transplant death. How-
ever, it is difficult to determine from these data whether
this was a significant causative factor to death or a marker
of worsening morbidity. Finally, female sex was an in-
dependent predictor of adverse outcome in this study,
and this is most likely due to the low number of
women in our cohort who subsequently underwent
transplantation. Compared to other studies, the rates
of graft loss and patient death were higher, most likely
reflecting higher degree of co-morbidity in patients re-
ferred for CV assessment.
This study has limitations. The time from CV assess-
ment to transplantation was not consistent and may act
as a confounder for prognostic cardiovascular modelling.
In addition, there is a lack of post-transplant LV and LA
data. However, our previous study demonstrating no
changes in CMR measured LV dimensions after trans-
plantation suggests that abnormalities present at assess-
ment prior to transplantation persist during the follow-up
of RTRs [9].
The aim of this study was to highlight potentially
modifiable CV risk factors before and after transplant-
ation. Newer strategies are required to improve uremic
cardiomyopathy and LA abnormalities in patients with
advanced stages of chronic kidney disease, given its ef-
fect on patient outcome even after renal transplantation.
However, the presence of LVH or LA dilation at the time
of CV assessment should not act as a barrier to trans-
plant listing given that renal transplantation is one of
the few interventions reliably shown to improve out-
comes in patients with CKD 5 [9].
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In conclusion, the presence of LVH and LA dilation are
significant predictors of death in patients who are listed
and subsequently proceed with renal transplantation.
Future studies should target LA dilation and LVH preven-
tion and progression whilst awaiting renal transplantation
in an attempt to reduce CV mortality in the long-term
follow-up of these patients.
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